Overcoming limitations of current antiplatelet drugs: A concerted effort for more profitable strategies of intervention
Key result
Antiplatelet treatment with aspirin and thienopyridines reduces non-fatal myocardial infarction by 32%, non-fatal stroke by 25%, and cardiovascular death by 17%, though residual risk persists.
Population
Patients at risk of atherothrombosis (acute myocardial infarction, ischemic stroke)
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
Supports antiplatelet regimens for ischemic reduction; leaves open personalized strategies to address residual risk.
Structured PICO
P
Population
Patients at risk of atherothrombosis (acute myocardial infarction, ischemic stroke)
I
Intervention
Antiplatelet therapy (aspirin, thienopyridines, and newer agents)
While current antiplatelet therapies significantly reduce ischemic events, their limitations regarding residual risk and bleeding underscore the need for personalized pharmacological strategies.
Cite This Study
Minno et al. (2011) conducted a review in Atherothrombosis and acute ischemic complications. Antiplatelet drugs (aspirin and thienopyridines) was evaluated. Antiplatelet treatment with aspirin and thienopyridines reduces non-fatal myocardial infarction by 32%, non-fatal stroke by 25%, and cardiovascular death by 17%, though residual risk persists.